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On February 27, 2002, the liver allocation system
changed from a status-based algorithm to one using
a continuous MELD/PELD severity score to prioritize
patients on the waiting list. Using data from the Sci-
entific Registry of Transplant Recipients, we examine
and discuss several aspects of the new allocation, in-
cluding the development and evolution of MELD and
PELD, the relationship between the two scoring sys-
tems, and the resulting effect on access to transplan-
tation and waiting list mortality. Additional considera-
tions, such as regional differences in MELD/PELD at
transplantation and the predictive effects of rapidly
changing MELD/PELD, are also addressed.
Death or removal from the waiting list for being too
sick for a transplant has decreased in the MELD/PELD
era for both children and adults. Children younger than
2 years, however, still have a considerably higher rate
of death on the waiting list than adults.
A limited definition of ECD livers suggests that they
are used more frequently for patients with lower MELD
scores.
Notes on Sources: The articles in this report are based on the
reference tables in the 2003 OPTN/SRTR Annual Report, which
are not included in this publication. Many relevant data appear
in figures and tables included here; other tables from the Annual
Report that serve as the basis for this article include the following:
Tables 9.1, 9.2, and 9.3. These tables are also available online at
http://www.ustransplant.org.
Funding: The Scientific Registry of Transplant Recipients (SRTR)
is funded by contract #231-00-0116 from the Health Resources
and Services Administration (HRSA). The views expressed herein
are those of the authors and not necessarily those of the US Gov-
ernment. This is a US Government-sponsored work. There are no
restrictions on its use.
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Introduction
The application of a statistical model to liver allocation rep-
resents a sea change in the evolution of organ allocation
policy. In the past, most organ allocation policy was devel-
oped using a consensus of opinion regarding the issues at
hand, with little in the way of statistical analysis, mathe-
matical derivation, or validation of principles. As organ al-
location has become more scrutinized, a more transparent
and justifiable method has become necessary. In this arti-
cle, we report on the rationale and development of the new
continuous disease severity scale based on the Model for
End-stage Liver Disease (MELD) and Pediatric End-stage
Liver Disease (PELD) scores. We outline the early results
of liver allocation under this new system and address the
regional variation that still exists. Lastly, we describe ad-
ditional analyses performed by the Scientific Registry of
Transplant Recipients (SRTR) that illustrate the utility of
this system for measuring results and analyzing transplant
center behavior.
Unless otherwise noted, the statistics in this article come
from reference tables in the 2003 OPTN/SRTR Annual
Report. Two companion articles in this report, ‘Trans-
plant data: sources, collection, and caveats’ and ‘Ana-
lytical approaches for transplant research’, explain the
methods of data collection, organization, and analysis that
serve as the basis for this article (1,2). Additional detail
on the methods of analysis may be found in the ref-
erence tables themselves or in the Technical Notes of
the OPTN/SRTR Annual Report, both available online at
http://www.ustransplant.org.
Development and Validation of MELD
In the early 1980s, as liver transplantation became an in-
creasingly successful procedure in the USA, donor livers
were shared on a voluntary ad hoc basis. The growing num-
ber of successful liver transplant programs suggested the
need for a more formal organ allocation system—for all
solid organs. In 1987, the US Government responded by
establishing the Organ Procurement and Transplantation
Network (OPTN), which has been operated under Federal
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contract. Since 1987, attempts to improve and standardize
organ allocation have been ongoing and evolving.
The earliest system of liver allocation employed a ‘sickest-
first’ principle, with some priority also given to time spent
on the transplant waiting list. Initially, the allocation scheme
was based on patient location. Patients in an intensive care
unit (ICU) received first priority, followed by patients re-
quiring continuous hospitalization, and lastly patients who
were being cared for at home. As the waiting list for liver
transplantation continued to grow, waiting time became a
major factor among patients in any given location, deter-
mining who received an organ and who did not. One prob-
lem with this allocation system was its lack of standards for
what constituted appropriate criteria for admission to the
ICU or continuous hospitalization. Indeed, many makeshift
ICUs were established merely for the purpose of advantag-
ing patients for transplantation. In addition, because wait-
ing time was a determinate factor, patients were added to
the waiting list years before they actually needed a trans-
plant merely to accrue waiting time.
These issues led to the convening of a consensus devel-
opment conference in 1996 organized by the American
Association for the Study of Liver Disease, the Interna-
tional Liver Transplant Society, and American Society of
Transplant Physicians, to establish minimal listing criteria
for liver transplantation and to design a new allocation sys-
tem based on disease severity (3). Following the confer-
ence, the Child-Turcotte-Pugh (CTP) scoring system was
adopted as the measure of liver disease severity to be uti-
lized in allocation (4–7). In addition, a separate Status 1
category was created for patients with fulminant hepatic
failure, primary nonfunction of a liver transplant, or hepatic
artery thrombosis diagnosed within 7 days of transplanta-
tion, as well as patients with acute decompensated Wil-
son’s disease. Status 1 candidates were given the highest
priority for donor organs (7). Patients with chronic liver dis-
ease were grouped into three categories: Status 2A (CTP
score ≥10 and less than 7 days predicted survival), Status
2B (CTP score ≥10 or CTP score ≥7 with major compli-
cations of portal hypertension), and Status 3 (CTP score
≥7). The waiting list, however, continued to grow to nearly
19 000 patients, leading to an ever-increasing waiting time
for transplant candidates. With only three defined cate-
gories for patients with chronic liver disease, waiting time
became a dominant factor in organ allocation. Waiting time
as an allocation factor became less acceptable when two
published studies documented conclusively that waiting
time was not associated with increased death on the wait-
ing list (8,9). Waiting time and the CTP score were imper-
fect components of the allocation system. Waiting time
was not reflective of medical need for transplantation, and
the CTP score, which had subjective elements that could
be manipulated and had never been validated for predicting
mortality on a waiting list, led to a failure of the system to
accurately prioritize large numbers of patients waiting for
donor livers.
In 1998, the Government published a Final Rule clearly stat-
ing that waiting time should be de-emphasized as a major
component of organ allocation. The Final Rule requires that
the allocation policies be based on sound medical judgment
using defined criteria to achieve the best use of donated
organs and avoid wasting of organs (10).
In response to this mandate, the OPTN appointed a sub-
committee of the Liver and Intestinal Transplantation Com-
mittee to develop and carefully assess an appropriate
model to meet these criteria. Following a careful review
of the literature and examination of existing liver disease
survival models, the committee decided to further assess
the Mayo End-stage Liver Disease model (later renamed
Model for End-stage Liver Disease, or MELD) as a basis
for a liver allocation policy. MELD, which had been devel-
oped to assess the short-term prognosis of patients under-
going transjugular intrahepatic portosystemic shunt (TIPS)
procedures (11), was based on four simple variables, in-
cluding three biochemical values (serum creatinine, serum
bilirubin, and international normalized ratio, or INR, of pro-
thrombin time) and the etiology of the liver disease.
It had been previously shown that survival following por-
tosystemic shunt surgery is mainly determined by the
severity of the underlying liver disease. Therefore it was
hypothesized that the MELD model could be used as a
prognostic indicator for all patients with advanced chronic
liver disease and potentially could be applied to prioritizing
patients on the waiting list for a liver transplant (12). The
model had the advantage that it relied mainly on objective
and standardized laboratory tests, which are readily avail-
able and reproducible throughout the country. None of the
parameters in the model were subjective or had political
overtones, such as age or race, that might make imple-
mentation controversial.
The MELD model was developed to determine the short-
term prognosis of patients undergoing a TIPS procedure;
therefore its prognostic value needed to be validated
across a wide spectrum of liver disease etiology and sever-
ity. The questions regarding MELD and its validation in-
cluded the following: (i) Would it predict who would live and
who would die among patients with decompensated and
compensated cirrhotic stage disease? (ii) Was the model
valid across all liver disease etiologies? (iii) Was it depen-
dent on other important factors involved in chronic liver
disease, such as complications of portal hypertension? (iv)
Would it predict who would die on the waiting list? (v) Could
use of such a model for allocation reduce deaths on the
waiting list and make allocation more equitable?
To validate the MELD model, 282 adult chronic liver disease
patients hospitalized at the Mayo Clinic between January
1994 and January 1999 were studied retrospectively (13).
Patients with advanced hepatocellular cancer and those
having advanced cardiopulmonary comorbidity were ex-
cluded from the analysis. Patient survival was assessed
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Table 1: Relationship between MELD, CTP score, and 3-month mortality in hospitalized cirrhotics (Group A)
≤9 10–19 20–29 30–39 ≥40
MELD Score
3-Month death rate 4 (6/148) 27 (28/103) 76 (16/21) 83 (5/6) 100 (4/4)
CTP Score A B C
3-Month death rate 4 (3/77) 14 (13/93) 51 (35/69)
Note: values expressed as percentages (number/total). Source: Kamath et al., 2001 (13).
from the day of hospitalization until death or last follow-
up. Because the aim was to validate the MELD score as a
severity index of liver disease to predict short-term mortal-
ity, 3-month mortality was chosen as the primary outcome
measure, but 1-year outcomes were also assessed. The
validity of the logistic regression model was determined
using a c-statistic to evaluate the area under the receiving
operating characteristic curve (14). In addition, overall mor-
tality based on baseline MELD and CTP scores were as-
sessed (Table 1). The baseline MELD score appeared to be
as good or better than the CTP score in predicting mortal-
ity, and had the advantage of employing variables that are
available, standardized, reproducible, and objective. With
this initial positive study, assessment of patient survival
using the MELD score was validated in three other groups
of patients including patients with compensated cirrhosis,
cholestatic liver disease, and decompensated cirrhosis. In
all instances, the MELD score was found to be an excellent
predictor of 3-month mortality, with a c-statistic ranging
from 0.80 to 0.87 (15).
An additional question was whether complications of por-
tal hypertension (e.g. ascites, encephalopathy, or variceal
bleeding) affect the ability of the MELD score to predict
mortality risk. Their inclusion in the model added little im-
provement in fit to predicted 3-month mortality. Similarly,
etiology was found to contribute very little to MELD’s pre-
dictive power. The investigators concluded that a MELD
score made up of the three laboratory values could be used
without data on complications of portal hypertension and
etiology (14).
The last and most important study to be completed to val-
idate MELD applied the model to the national waiting list
(16). In this study, the MELD equation was altered so that
all laboratory values <1 were rounded up to 1.0 to prevent
coefficients with negative values. The etiology variable was
removed from the original equation in response to the pre-
vious study showing that this factor contributed little addi-
tional predictive value (Figure 1). Between November 1999
and December 2001, MELD values were studied in 3437
adult liver transplant candidates with chronic liver disease
who were added to the waiting list at Status 2A or 2B.
Of this cohort, 412 (12%) died during the initial 3 months
of follow-up. Waiting list mortality increased directly in pro-
portion to the MELD score at listing (Figure 2). As shown in
Figure 3, the c-statistic with 3-month mortality as the end-
point was 0.83 for MELD, compared with 0.76 for the CTP
score (p < 0.001); a larger area under the receiver operating
















Source: Wiesner et al, 2003. (14)
Figure 2: Three-month mortality based on listing MELD in pa-
tients on the OPTN waiting list.
characteristic (ROC) curve indicates better predictive accu-
racy for the 3-month mortality endpoint. These data sug-
gested that the baseline MELD score accurately predicts
3-month mortality among patients with chronic liver dis-
ease on the liver waiting list, and therefore could be applied
usefully for allocation of donor livers (Table 2).
Policy developers recognized that the MELD and PELD
scores would not serve all candidates for liver transplan-
tation equally well. The most important ‘exceptional’ diag-
nosis was hepatocellular carcinoma (HCC). Recent studies
had suggested that excellent results could be achieved for
liver transplant candidates with early-stage HCC (17–19),
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but that prolonged waiting times increased the dropout
rate and diminished these results when liver transplanta-
tion was assessed in an intention-to-treat approach (20,21).
Most of these candidates face a risk of tumor progression
that is greater than their risk of death and therefore some
estimate of the risk of tumor progression was necessary to
incorporate these patients into the new system. By equat-
ing this risk of progression with the risk of death as de-
fined by the MELD score, a similar priority score could be
assigned for these patients (22). Initially, OPTN policy esti-
mated this risk at 15%, corresponding to a MELD score of
24 for candidates meeting Stage I criteria, and 30% (MELD
score of 29) for Stage II patients (23). Early experience with
the new system revealed that the dropout rate for HCC
candidates was extremely low and that candidates with-
out HCC but with similar MELD scores had higher mortal-
ity rates compared with the HCC patients. (Tables 3 and 4)
For this reason, in April 2003 the HCC ‘exceptional’ MELD
points were reduced to 20 and 24 for Stage I and Stage II
candidates, respectively.
The OPTN also recognized that other rarer diagnoses and
special circumstances might also arise in which MELD
score would not be a good determinant of the need for a
liver transplant. The new policy provided for the other ‘ex-
ceptional’ cases by developing a regional peer-review pro-
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Source: Wiesner et al. The model for end-stage liver disease (MELD) and allocation of donor livers.
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Figure 3: Area under the receiver operating characteristic (ROC)
curve for the MELD and CTP models.
Table 2: Comparison of MELD and CTP allocation schemes
MELD allocation scheme CTP allocation scheme
Development & rationale TIPS outcome Surgical shunt outcome
Assessment Prospective Empiric
Parameters Objective Some are subjective
Variability Minimal Center-to-center interpretation
Spectrum Continuous Ceiling effect, categorical
Validation Yes No
Allocation emphasis Disease severity Waiting time
Source: SRTR.
the responsibility of reviewing centers’ applications for in-
creased priority for these exceptional cases. If the RRB
finds that the clinical circumstances of an individual case
represent greater need as determined by the center’s ap-
plication for a higher MELD score, then the candidate is
assigned that higher score. In cases where the RRB does
not agree with the center’s assessment, the center is free
to appeal the RRB decision or reapply for a different MELD
score.
At the time of organ offer, candidates are prioritized by
their ‘match score’. For patients without RRB-approved
requests for an increased MELD score, the match score
is simply the MELD score as calculated by laboratory val-
ues alone. For patients with RRB-approved MELD score
requests, their match score is the new RRB-approved
score. A full description of the OPTN policy has been
published (23) and the current policy can be found at
http://www.optn.org.
Pediatric End-Stage Liver Disease (PELD)
Score
Development and validation of PELD criteria
Concurrent with the development of MELD, the pediatric
hepatology community developed a similar scoring sys-
tem relevant to the unique characteristics of children with
chronic liver disease. In contrast to the MELD score, which
was originally developed in a selected population of adult
patients with end-stage liver disease requiring a TIPS pro-
cedure (12), the PELD score was developed from data
representative of a cross-section of children awaiting liver
transplantation (24). These data derived from the Stud-
ies of Pediatric Liver Transplantation (SPLIT), a consortium
of 38 pediatric liver transplant centers that has been en-
rolling children eligible for liver transplantation in the USA
and Canada since 1995 (25). At the time of development
of PELD, the SPLIT database was enrolling approximately
50% of all children placed on the waiting list for a liver
transplant in the USA.
There was general agreement between the pediatric
and adult hepatology groups that the basic principles
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Table 3: Ninety-day transplant and mortality rates after wait-listing for liver (only), by calculated MELD/PELD laboratory score
Median Median
Calculated Mean lab Death MELD/PELD Transplant MELD/PELD
score n (Match) score rate1 (%) at death rate2 (%) at transplant
Adult Status 1 387 31.3 38.3 38 68.0 35
MELD: Lab
(no exceptions)
6–10 1277 8.4 1.6 10 5.6 9
11–10 3219 14.8 3.9 20 14.4 17
21–25 524 23 13.7 30 42.2 24
24 (104) 24 14.8 30 44.2 24
26–30 241 28 34.0 31 62.1 30
29 (47 ) 29 47.6 36 64.8 29
31–40 363 36.3 63.3 40 79.6 37
Overall 5624 16.0 8.2 33 22.1 22
MELD: HCC
24 77 12.6 5.9 24 43.9 24
29 388 11.9 5.6 29 76.1 29
Overall 465 12.0 5.6 29 70.7 29
Other non-HCC
exceptions
Adult 106 15.2 (28.1) 14.8 32 65.1 29
Pediatric 43 5.1 (29.7) 2.6 39 67.3 30
Pediatric Status 1 156 25.6 22.5 31 66.7 22
PELD: Lab
(No Exceptions)
(-11)-(-1) 60 –4.8 0.0 0 16.5 –3
0–10 115 5.0 1.8 5 15.3 7
11–20 113 15.0 3.2 16 34.1 17
21–30 62 24.5 13.9 25 43.7 25
31–40 13 34.8 19.2 33 42.3 29
41+ 9 56.8 33.3 46 66.7 49
Overall 372 12.0 7.8 25 37.0 18
1Censored at removal from the waiting list for reasons other than death.
2 Censored at removal from the waiting list for reasons other than cadaveric transplant.
Notes: Table 3 shows the 90-day outcomes by the MELD/PELD distribution for all patients including the average MELD/PELD score
at death and transplant. Similarly, Table 4 shows the 30-day outcomes by MELD/PELD distribution. The study population includes all
patients on the liver waiting list that were added between 2/27/02 and 11/28/02 for the 90-day outcome tables and 2/27/02 and 1/27/03
for the 30-day outcome tables. Patients waiting for a liver-intestine were excluded from the analyses. NonStatus 1 patients granted an
exception within 30 days of the date of listing had the exception score used for calculation of their match MELD/PELD. Similarly, the
first exception MELD/PELD score granted within 30 days of wait-listing for patients listed between 2/27/02 and 1/27/03 (or 11/28/02
for 90-day outcomes) was used for calculation of the match MELD/PELD score. Follow-up time (start date) began on the listing date
for nonexception patients listed between 2/27/02 and 1/27/03 (or 11/28/02 for 90-day outcomes), and on the date of the exception for
patients receiving an exception score. Patients with automatically assigned a MELD/PELD score of 6 were allowed to have their start
date delayed for up to 30 days if an updated score became available during this time. All patients were followed for 30 and 90 days
from the start date. Unadjusted Cox regression models were used to model 30-day and 90-day rates of transplantation and death on the
waiting list. Time to transplant models were censored at the earlier of waiting list removal for reasons other than cadaveric transplant
(including death) or 30 days (or 90 days). Time to death models were censored at removal from the waiting list for reasons other than
death (including transplant) or 30 days (or 90 days). Modeling the transplantation and death rates in this manner addressed the problem
of the competing risks of transplantation and death. Status 1 patients were analyzed separately.
Source: SRTR analysis. Data as of August 1, 2003.
underlying the development of MELD and PELD should
be the same, and that only objective verifiable parameters
would be included to avoid the possible bias of subjec-
tive assessments such as ascites or encephalopathy (15).
Events such as variceal bleeding and spontaneous bacte-
rial peritonitis would not be included in the scoring system,
based on previous studies showing that the outcome of
such events was dependent on the severity of the under-
lying liver disease, rather than the events themselves in
children (26) and adults (27). It was also agreed that the
number of parameters in the model would be limited so
that calculations of the score would be straightforward.
Development and testing of both models would use a sim-
ilar statistical methodology (c-statistic). Like MELD, death
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Table 4: Thirty-day transplant and mortality rates after wait-listing for liver (only), by calculated MELD/PELD laboratory score
Median Median
Calculated Mean lab Death MELD/PELD Transplant MELD/PELD
score n (Match) score rate1 (%) at death rate2 (%) at transplant
Adult Status 1 471 31.4 35.1 38 66.8 34
MELD: lab
(no exceptions)
6–10 1487 8.5 0.4 17 2.3 9
11–10 3807 14.8 1.0 19 6.2 17
21–25 636 23 4.1 29 20.7 24
24 (126) 24 5.4 32 22.8 24
26–30 305 28 19.7 31 45.0 29
29 (60) 29 29.1 29 42.7 29
31–40 458 36.2 43.1 40 64.9 37
Overall 6693 16.2 4.8 36 14.4 26
MELD: HCC
24 94 12.9 1.2 24 25.9 24
29 489 12.0 1.3 29 47.1 29
Overall 583 12.2 1.3 29 43.7 29
Other non-HCC
exceptions
Adult 124 15.1 (27.8) 8.5 32 39.5 29
Pediatric 47 5.5 (29.7) 2.3 39 33.3 29
Pediatric Status 1 195 26.2 22.8 31 53.8 23
PELD: lab
(no exceptions)
(-11)-(-1) 71 –4.9 1.5 –3 4.6 –3
0–10 134 5.1 1.5 5 6.8 7
11–20 142 15.1 2.9 16 16.3 17
21–30 74 24.4 4.6 29 22.4 25
31–40 15 34.7 17.5 33 13.3 26
41+ 11 55.1 40.0 32 54.5 49
Overall 447 12.1 7.1 18 23.7 19
1Censored at removal from the waiting list for reasons other than death.
2Censored at removal from the waiting list for reasons other than cadaveric transplant.
Notes: Table 4 shows the 30-day outcomes by the MELD/PELD distribution for all patients including the average MELD/PELD score
at death and transplant. Similarly, Table 3 shows the 90-day outcomes by MELD/PELD distribution. The study population includes all
patients on the liver waiting list that were added between 2/27/02 and 11/28/02 for the 90-day outcome tables and 2/27/02 and 1/27/03
for the 30-day outcome tables. Patients waiting for a liver-intestine were excluded from the analyses. NonStatus 1 patients granted
an exception within 30 days of date of listing had the exception score used for calculation of their match MELD/PELD. Similarly, the
first exception MELD/PELD score granted within 30 days of wait-listing for patients listed between 2/27/02 and 1/27/03 (or 11/28/02
for 90-day outcomes) was used for calculation of the match MELD/PELD score. Follow-up time (start date) began on the listing date
for nonexception patients listed between 2/27/02 and 1/27/03 (or 11/28/02 for 90-day outcomes), and on the date of the exception for
patients receiving an exception score. Patients with an automatically assigned MELD/PELD score of 6 were allowed to have their start
date delayed for up to 30 days if an updated score became available during this time. All patients were followed for 30 and 90 days
from the start date. Unadjusted Cox regression models were used to model 30-day and 90-day rates of transplantation and death on the
waiting list. Time to transplant models were censored at the earlier of waiting list removal for reasons other than cadaveric transplant
(including death) or 30 days (or 90 days). Time to death models were censored at removal from the waiting list for reasons other than
death (including transplant) or 30 days (or 90 days). Modeling the transplantation and death rates in this manner addressed the problem
of the competing risks of transplantation and death. Status 1 patients were analyzed separately.
Source: SRTR analysis. Data as of August 1, 2003.
at 3 months on the waiting list was the primary endpoint.
A second composite endpoint of death or moving to the
ICU before transplant was also examined, as described
elsewhere (24), but was not incorporated into the PELD
score because it did not improve the predictive value.
The SPLIT data analyses included Kaplan-Meier estimates
of the probability of death on the waiting list for 18 dif-
ferent variables. For the development of PELD, six vari-
ables were selected based on statistical significance and
agreed-upon principles of model development. These were
bilirubin, INR, calculated glomerular filtration rate (GFR),
serum albumin, age, and growth failure. There were 884
children evaluable for the endpoint of death on the waiting
list. From the multivariate analyses, the significant factors
that were incorporated into the PELD score were bilirubin,
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Source: SPLIT and SRTR analyses, October 2003.
Figure 4: Predicted probability of waiting list death at 3 months
by severity scores.
INR, albumin, age < 1 year, and growth failure (defined as
height or weight more than two standard deviations be-
low normal for age and gender). The c-statistic for death
at 3 months on the waiting list was 0.92 (95% confidence
interval 0.85–0.99) (24). Mazariegos et al. independently
validated the PELD score and confirmed its ability to pre-
dict death on the waiting list in a large single-center data
set (28).
A comparison of the probability of death at 3 months for a
given PELD or MELD score is shown in Figure 4. The figure
shows the initial curve generated from the SPLIT database
for PELD, as well as curves based on national waiting list
data since the implementation of MELD and PELD. Note
that the PELD curves fall to the right of the MELD curves at
higher scores, meaning that for a given score in this range
the probability of death on the waiting list is less for a child
than for an adult. In contrast, at lower scores the mortality
risk associated with PELD is higher than associated with
MELD. It was decided, however, to accept the PELD score
without an adjustment factor that would attempt to equate
the probability of death on the waiting list for a given score
between children and adults. This has the effect of giving
children who are somewhat less ill than adults with the
same score the same level of priority, potentially directing
appropriate organs to children at a less severe stage in their
disease. In addition, the new policy respects the previous
policy of trying to direct pediatric organs to pediatric recip-
ients and maintains the stipulation that pediatric patients
with chronic liver disease who require ICU care may be
designated Status 1.
Effects on the liver waiting list
Since the implementation of MELD and PELD, the pediatric
transplant community has been studying their effects on
wait-listed children. With the increasingly dominant num-
ber of adults on the liver waiting list, access of pediatric
patients to transplants under the new allocation system is
of concern. Figure 5 shows the reasons for removal from
the waiting list for pediatric and adult patients before and
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Source: SRTR Analysis. Data as of August 1, 2003.
Figure 5: Reasons for removal from the liver waiting list before
and after implementation of MELD/PELD.
2/26/02 and 2/27/02–2/26/03, respectively). In the period
before MELD/PELD, 10 944 patients were added to the
liver waiting list, of which 1035 (10%) were children, com-
pared with 856 (9%) in the MELD/PELD period. Overall,
47% of adults were removed for deceased donor trans-
plant in the pre-MELD/PELD era compared with 49% in the
MELD/PELD era. For children, the comparable figures are
49% pre-MELD/PELD and 53% post-MELD/PELD. These
data suggest that under the new allocation system, the
percentage of children and adults on the waiting list who
received a deceased donor organ increased slightly be-
tween the two periods. From Figure 5 it can also be seen
that the number of children who died or became too sick
to transplant dropped in the MELD/PELD period, and that
for both children and adults, there was a reduction in liv-
ing donor transplants between the two periods. There was
also an increase in removals from the list for ‘other’ rea-
sons in the MELD/PELD period. This increase in removals
for ‘other’ reasons probably occurred because when
centers were required to re-examine wait-listed patients
when the MELD/PELD system was implemented, they
may have then found patients who were not appropriate
candidates for transplantation.
Ninety-day outcomes on the waiting list by
laboratory MELD/PELD score
Table 3 shows the 90-day outcomes for adults and chil-
dren on the waiting list. Relative rates of death and de-
ceased donor transplant were examined for all patients
added to the list between 2/27/02 and 11/28/02. Mean and
median laboratory PELD and MELD scores at the time of
deceased donor transplant or death were included. (Lab-
oratory MELD/PELD scores are based on laboratory data
and do not include additional points assigned by regional re-
view boards.) Separate unadjusted Cox regression models
were used to model death and transplant by MELD/PELD
category or Status 1, and liver-intestine candidates were
excluded. Comparing adult patients (n = 5624) to the pe-
diatric patients (n = 372) 90 days after listing, the rates
of death were nearly the same (both approximately 8%),
whereas 37% of children compared with 22% of adults re-
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ceived a deceased donor transplant, and 5.9% of children
compared with 0.9% of adults received a living donor trans-
plant. Removal from the list for being too sick for transplant
was 0.5% for children compared with 1.2% for adults. The
median lab MELD/PELD score at deceased donor trans-
plant was 18 for children and 22 for adults, whereas a larger
difference was found in the median MELD/PELD score
at death for adults and children (33 and 25, respectively).
Overall, compared with adult candidates, a higher propor-
tion of children received deceased and living donor trans-
plants and a lower proportion of children were removed for
death or being too sick. In general, children received their
deceased donor transplants at lower PELD scores than the
adults. These results suggest that children’s transplanta-
tion rates/removal rates were not adversely affected by
the new system.
PELD score at listing and time of transplantation
Table 5 shows the mean and median laboratory PELD
scores at listing by age range for children listed between
2/27/02 and 3/30/03 and by transplant number (no pre-
vious transplant vs. previous transplant). At listing, chil-
dren younger than 1 year had the highest PELD scores
and those between 6 and 10 years had the lowest. Chil-
dren with a previous transplant tended to have a higher
PELD score at listing. The mean and median PELD scores
comparing blood type are relatively similar, as is shown in
Table 6.
For the period 2/27/02–2/26/03, the mean and median allo-
cation MELD or PELD score (the score at the time of alloca-
tion, or ‘match score’, which includes scores by exception)
is shown for adult and pediatric patients in Table 7. This is
compared with the lab MELD/PELD score. For both labora-
tory and allocation (match) scores, pediatric candidates are
receiving their transplants at lower values compared with
adults. However, the scores are similar for removal due to
death or too sick for children compared with adults, as seen
in Table 8. Figure 6 shows deaths adjusted per 1000 patient
years on the waiting list comparing adults and children be-
fore and after the implementation of MELD and PELD. In
both periods, the death rate for all children was lower than
for adults. For children <1 and <2 years of age at listing,
however, the death rate was considerably higher than for
adults. Currently, there are 224 deaths per 1000 patient
years for children aged <2 years, compared with 137 for
adults. This is an increase from 183 per 1000 patient years
death rate for young children prior to the implementation
of PELD and MELD.
Table 9 shows the percentage of children listed (excluding
Status 1) for ranges of the allocation PELD score, and the
percentage of children transplanted at ranges of the allo-
cation PELD score. The highest proportion of children are
listed and transplanted at a PELD score of < 10. Figure 7
shows the considerable variation in distribution of alloca-
tion PELD scores (excluding Status 1) by region at the time
Table 5: Mean and median PELD at listing by age and previous
transplant
Categories
Age at listing Mean PELD Median PELD
<1 years 19.3 18.0
1–5 years 14.3 13.0
6–10 years 10.8 7.0




Source: OPTN/SRTR data as of August 1, 2003. Includes all
listings between 2/27/02 and 3/30/03.
Table 6: Mean and median PELD at listing by blood type





Source: OPTN/SRTR data as of August 1, 2003. Includes all
listings between 2/27/02 and 3/30/03.
Table 7: Mean and median laboratory and match MELD/PELD
scores by status and age, deceased donor transplants
Age group Mean MELD/PELD Median MELD/PELD
Adult
Laboratory score 19.3 17.0
Match score 21.0 24.0
Pediatric
Laboratory score 9.9 9.0
Match score 17.6 17.0
Source: OPTN/SRTR data as of August 1, 2003. Includes all
transplants between 2/27/02 and 2/26/03. Laboratory scores are
based on laboratory values alone; match scores include points
from RRB-approved exceptions.
of listing and at the time of transplant. Some of this vari-
ation is due to the small number of pediatric transplants
performed in some regions.
Pediatric donor to pediatric recipient policy
A previous study from the SRTR showed that the odds of
graft failure were reduced significantly if pediatric recipi-
ents received livers from pediatric donors (<18 years of
age) (29). This study resulted in a change in liver alloca-
tion policy in 2000 to preferentially allocate pediatric donor
livers to pediatric recipients with medical urgency status
and according to the usual geographic distribution rules.
In order to preserve this concept under the MELD/PELD
allocation policy, it was decided that livers from pediatric
donors would be allocated first to those pediatric candi-
dates with probability of death within 90 days greater than
50%. This policy was established without data to assess
its effect. A preliminary analysis compared recipient age for
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Table 8: Mean and median laboratory and match PELD scores by
removal reason and age
Categories Mean PELD Median PELD
Death
Adult
Laboratory score 23.5 21.0
Match score 18.8 19.0
Pediatric
Laboratory score 21.8 23.0
Match score 22.3 23.0
Too sick
Adult
Laboratory score 21.6 19.0
Match score 20.0 20.0
Pediatric
Laboratory score 21.0 22.5
Match score 24.2 23.5
Source: OPTN/SRTR data as of August 1, 2003. Includes all
transplants between 2/27/02 and 2/26/03. Laboratory scores are
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Source: SRTR Analysis. Data as of August 1, 2003.
Figure 6: Deaths per 1000 patient years on the liver waiting list
before and after implementation of MELD/PELD.
865 pediatric donors prior to MELD/PELD to 828 pediatric
donors since its implementation (Figure 8). Overall, adults
received 60% of pediatric donor livers before MELD/PELD
and 54% after its implementation. Organs from older pedi-
atric donors (9 years or older) were much more likely to be
placed into adult recipients than pediatric recipients: 83%
before MELD/PELD and 77% afterward. This suggests ei-
ther that there were no pediatric candidates in the local
distribution area available at the time of the pediatric organ
offer or that the system has not been successful in pref-
erentially directing pediatric organs to pediatric recipients.
Additional analyses will be required to determine the cause
for these findings.
Change in PELD score and death before transplant
It has been shown that changes in the MELD score while
waiting have a significant effect on the chance of dying
prior to transplant. Adults with increasing MELD scores
over time have a higher probability of death while wait-
ing, and conversely adults whose MELD scores decreased
Table 9: Percentage of children listed and transplanted at alloca-
tion PELD score ranges
Percentage Percentage
PELD groups at listing at transplant







40 + 1.3 10.4
Source: OPTN/SRTR data as of August 1, 2003. Includes listings



















PELD at Listing PELD at Transplant
Source: SRTR Analysis. Data as of August 1, 2003.
Figure 7: Mean PELD score at listing and at transplant, by region.
over time had a decreased chance of death on the waiting
list (30). An analysis was undertaken to see if the same
findings applied to pediatric candidates awaiting liver trans-
plantation (Table 10). The change in PELD score over the
prior 30 days (PELD) was included in a Cox model in
which the time at risk for all patients began at 30 days from
the time of listing. Deaths and changes to Status 1 before
day 30 were not included in the mortality model. All pa-
tients were followed in a time-dependent Cox model from
day 30 until whatever came first: death, change to Status
1, or December 1, 2002. Despite the relatively small num-
ber of events (21 events among the 393 pediatric candi-
dates in the study), the effect of an increasing PELD was
found to significantly increase the relative risk of death on
the waiting list (RR = 1.10, p < 0.0001). The PELD was
also a significant predictor of waiting list mortality for an
increase of greater than 5 points (RR = 5.98, p = 0.0005).
A decreasing PELD also showed an adverse trend on
waiting list survival, although this did not reach statistical
significance. This might be explained by the finding that
patients with a decreasing PELD were found to have a
corresponding increase in serum albumin. An increase in
albumin would lower the PELD score, despite the fact that
































Source: SRTR Analysis. Data as of August 1, 2003.
Figure 8: Comparison of recipient age of pediatric donor organs
before and after implementation of MELD/PELD.
Table 10: Relative risk of waiting list mortality by PELD, ad-
justed for PELD score
PELD over PELD changes
prior 30 days n (events) RR p-value
Decreasing (slope < 0) 268 (4) 2.36 0.219
Stable(0 ≤ slope ≥ 5) 761 (9) 1.00 (reference)
Increasing (slope > 5) 140 (8) 5.98 0.0005
Source: SRTR final analysis for the OPTN Liver-Intestine Commit-
tee, February 21, 2003.
artificially increasing the albumin by infusions would indi-
cate a worsening condition.
PELD score and mortality risk, liver only vs.
liver-intestine transplant
Up to 40% of children awaiting liver-intestine transplant die
before receiving the transplant. This is particularly a prob-
lem for the youngest candidates (31). The difficulty lies in
finding appropriate sized organs for candidates for liver-
intestinal transplantation. Using OPTN/SRTR data, deaths
on the waiting list for pediatric candidates were analyzed,
comparing liver only candidates to liver-intestine candi-
dates. Between July 1, 1997 and June 30, 2000, 2171 chil-
dren were listed for liver only, compared with 227 listed
for a liver-intestine transplant. As can be seen in Figure 9,
survival on the waiting list was lower for the children re-
quiring liver-intestine transplant, and this was particularly
evident for those aged less than 1 year. A further analy-
sis showed that for a given PELD score, death rates were
3.6 times higher for liver-intestine candidates (p = 0.01)
than for liver only patients. The PELD score itself does not
predict waiting list mortality differently for liver only com-
pared with liver-intestine patients. Using the PELD equa-
tion, the 3.6-fold increase in the average relative risk of
death equated to 12 points for the ‘average’ pediatric pa-
tient. This finding led to modification of the waiting list pol-
icy for children listed for liver-intestine transplant, who now
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Source: SRTR Analysis for the OPTN Pediatric Committee, 
July 24, 2002, Table 2.2. 
Figure 9: Three-month waiting list survival probabilities for pedi-
atric liver and liver-intestine candidates.
tal 10% risk of 3-month mortality above what their stan-
dard PELD score would indicate. This policy was also ex-
tended to adult patients waiting on the list for liver-intestine
transplants.
The impact of PELD: summary
Since the institution of MELD/PELD, children do not appear
to be disadvantaged in their access to deceased donor liv-
ers as compared with adults. Children are handled in the
organ allocation policy preferentially by directing pediatric
organs preferentially to pediatric patients. Also, in contrast
to adult patients, pediatric patients with chronic disease
may be moved to Status 1 priority with admission to an
ICU. Death or removal due to becoming too sick for trans-
plant on the waiting list has decreased in the MELD/PELD
era for both children and adults. However, children younger
than 2 years of age still have a considerably higher rate of
death on the waiting list than adults. There is consider-
able variation by region in the PELD score at listing and at
transplant, suggesting that regional differences may exert
important effects on pediatric patients’ chances of trans-
plant. In assessing the 90-day outcome on the waiting list,
the percentage of children who receive a deceased donor
organ is somewhat higher than the percentage of adults,
and the proportion that die on the waiting list is somewhat
lower compared with adults. Further analyses with more
data and longer follow-up times are needed to determine
whether or not these differences are clinically and statisti-
cally important. The change in PELD score while awaiting
a transplant appears to be an important predictor of out-
come for children on the waiting list, as it is for adult pa-
tients. At least from preliminary results, the percentage of
pediatric donors allocated to children has risen slightly with
the implementation of MELD and PELD. Children awaiting
combined liver-intestine transplant have a high mortality
on the waiting list, justifying the assignment of a higher
PELD score than the calculated score to compensate for
the increased relative risk of death on the waiting list. Fi-
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nally, the important question as to the outcome of children
after transplantation in the MELD/PELD era awaits further
analyses.
Thirty-Day and 90-Day Waiting List
Outcomes
The implementation of the MELD and PELD systems has
allowed for the accurate estimation of the relative risk of
30-day mortality for patients on the waiting list for liver
transplantation. The information provided herein demon-
strates some of the early effects of these systems.
A logical first look at the data is to examine what the wait-
ing list looked like at the end of 2001 and compare this
to the waiting list at the end of 2002. The MELD system
was implemented in the first quarter of 2002; therefore the
year-end snapshot of the waiting list would demonstrate
the combined result of reclassification of candidates using
MELD/PELD.
At the end of 2001, 66% of the patients on the waiting
list were Status 3 (least urgent medical status at the time).
Status 2B (most urgent status outside of the intensive care
unit) comprised 17% of the patients, while less than one
per cent were Status 1 or Status 2A, usually meaning the
patients were in the ICU.
In 2002, the percentage of patients listed at Status 1 at
the year end was unchanged, an expected result because
the definition of Status 1 did not change. The percentage
of patients listed in the lowest MELD ranges total close
to the patients with the lowest status in 2001, suggesting
that there was not a marked change in characteristics of
patients listed or transplanted during the first 9 months
after MELD/PELD implementation.
An interesting finding is that the number of patients waiting
for transplantation decreased by more than 1000 in 2002.
This is primarily due to a decrease in new waiting list reg-
istrations, as there were approximately 1500 fewer regis-
trations than in either of the previous 2 years. It may be
speculated that the change in the system to MELD/PELD,
which markedly de-emphasized waiting time, may have led
centers to list patients more slowly because there is little
to be gained by pre-emptive listing. Although there was
an increase in the number of transplants in 2002 (approxi-
mately 300), this was not a major contributing factor to the
shrinking waiting list.
One unexplained finding is the dramatic increase in the
number of temporarily inactive patients. Through the
decade, the number of these patients has steadily in-
creased, and it is unclear why MELD/PELD would lead to
this change. At the time of implementation of MELD/PELD,
all centers were required to submit laboratory data in order
to assign a MELD/PELD score. Many centers may have
found that some of these patients were lost to follow-up,
had improved in condition or had died before the initiation
date, and therefore were removed for ‘other reasons’. The
MELD/PELD scores of new waiting list registrants shows
that the most frequent range of MELD points was 11–20,
more than twice as high as patients in the lower range. This
is of interest when compared with the year-end waiting list,
where the percentages are more similar. This difference
suggests that the new registrants are more ill than the pa-
tients previously added to the waiting list. There were a
substantial number of registrations for patients with hep-
atocellular carcinoma (HCC). A different trend was seen
among pediatric registrants, of whom the largest number
of registrants had PELD scores in the lowest range.
There is a marked association of increasing death rates on
the waiting list with higher MELD scores. There is a 58-
fold higher rate of death for patients listed with a score
of >30 as compared with patients listed in the lowest
MELD range. This near-logarithmic progression is a reflec-
tion of the steepness of the curve of 30-day survival plot-
ted against MELD score. A similar trend is seen in the
death rates in the pediatric population, but the small num-
ber of patients, particularly with the highest scores, may
hide a more dramatic increase. The death rate among Sta-
tus 1 candidates demonstrates a decade-long decrease.
The death rate in patients listed with HCC is relatively low,
which may hide the true risk of these candidates, who are
more likely to be removed from the waiting list prior to
death.
Table 4 presents a snapshot of what occurs within 30
days after listing for various ranges of MELD (using lab
MELD scores). While this table does not take into ac-
count changes in MELD score that occurred during this
period, it does show the effect of the MELD system. The
strong predictive gradient effect of the MELD score is seen
with increasing mortality as the MELD score increases.
Fortunately, it also appears that the 30-day transplant rate
is also strongly affected by MELD: as the MELD score
at the time of listing increases, the percentage of patients
transplanted rises. This is a very strong suggestion that the
MELD system works as designed. It appears to prioritize
patients for transplantation.
The PELD system does not appear to be faring as well in
terms of 30-day outcomes. There is not the steep gradient
of death rates that is seen in the MELD system—the slope
is relatively flat and increases sharply only at the higher
scores. A similar trend is seen for transplant rates, which
do not rise continuously with increasing scores. Some of
the effects of the PELD score may be hidden among Status
1 transplants. While Status 1 among adults is restricted to
candidates without chronic liver disease, there is no such
limitation among pediatric candidates. Some of the pedi-
atric recipients with the highest PELD scores may have
moved into the Status 1 category, effectively hiding the ef-
fect of the PELD score on prioritizing these patients in the
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Table 11: Waiting list status at transplant for deceased donor liver recipients, by region
Region
Waiting list status
at transplant (%) 1 2 3 4 5 6 7 8 9 10 11
Status 1 5.1 8.5 9.2 7.3 15.1 6.0 9.5 8.0 16.9 5.7 7.1
MELD 6–10 2.8 8.0 5.5 3.1 3.3 2.7 1.6 3.2 3.6 7.1 3.2
MELD 11–20 20.8 31.3 31.3 27.9 18.9 48.1 22.0 27.5 17.8 34.9 30.1
MELD 21–30 21.9 18.6 19.7 20.3 11.3 18.0 19.8 16.9 10.8 20.1 24.3
MELD > 30 17.4 10.8 9.0 8.7 20.3 5.5 11.8 12.6 13.8 5.5 11.6
PELD < 11 5.1 2.2 1.9 3.1 0.8 1.1 2.8 5.2 0.4 3.0 0.4
PELD 11–20 0.6 1.2 0.9 0.7 1.5 1.1 1.2 1.1 1.1 1.4 0.4
PELD 21–30 – 0.8 0.8 0.3 0.5 – 0.7 1.4 – 2.4 0.2
PELD > 30 0.6 0.1 – 0.2 0.2 – 0.2 – – 0.8 –
HCC T1 0.6 3.0 2.6 2.7 3.3 3.3 4.9 2.9 2.5 1.6 3.4
HCC T2 19.7 13.6 12.3 17.4 20.2 13.1 18.3 11.7 18.6 10.5 13.1
Other exceptions 5.6 1.9 6.7 8.3 4.6 1.1 7.1 9.5 14.4 7.1 6.0
Source: OPTN/SRTR data as of July 1, 2003. Includes transplants between 2/27/02 and 12/31/02.
Status 1 designation. The results of the PELD system at
90 days (Table 3) are more reassuring about the effective-
ness of the PELD system. Here, the death rates demon-
strate a better gradient and the transplant rates increase as
expected.
A striking finding of these analyses is the transplantation
rates among patients with exception MELD/PELD scores,
primarily those with HCC. These patients are given MELD
points to match a predefined risk of death in this patient
population. While the death rates for this group (Table 4) are
low, the major risk for these patients is that their tumors
may progress to a stage that would prevent transplanta-
tion. These patients were given a MELD score of 24 or
29 depending upon tumor stage. The effect of these ex-
ception scores is better demonstrated in Table 3, which
shows that nearly 71% of candidates received a transplant
within 90 days. Given these high rates of transplantation,
the exception points given to these candidates were de-
creased to 20 and 24 early in 2003 to lessen the advantage
and disparity. A preliminary review of 796 cases of can-
didates with increased priority due to their HCC meeting
criteria identified 666 cases for whom a pathology report
of the explanted liver was received by the OPTN. Review
of these pathology reports identified 2 (0.3%) cases of
cholangiocarcinoma, 11 (1.65%) cases of mixed hepato-
cholangiocarcinoma, 161 (25%) benign or indeterminate
lesions, and 488 (73.3%) with HCC. Three hundred and
eighty-three (43%) cases were treated with some form
of ablative therapy prior to transplant. Micro- or macro-
vascular invasion was present in 7% and 3% of cases,
respectively. The distribution of lesions by stage was: 23%
stage 0, 8% stage 1, 37% stage 2, 10% stage 3, 8% 4a,
and 12% 4b. Relative to the preoperative staging, 34% of
cases had a more advanced stage on the pathology report,
36% had no change and 8% had a histologic stage less
than preoperative stage. Twenty-two per cent had no can-
cer and 68 (10%) cases had no nodule and no evidence of
HCC. Of the 383 cases treated with ablative therapy, 99
had no HCC in the pathology report. Of the 32 cases for
which Stage I was requested who had ablation, seven had
no tumor, three had Stage I, and 22 had > Stage I histolog-
ically. Of the 269 cases for which Stage II was requested
and ablation was indicated 78/269 cases were histologi-
cally > Stage II, 115/269 were histologically = Stage II and
76/269 were histologically < Stage II and therefore down-
staged. Overall, a total of 83 cases were downstaged by
ablative treatment in this cohort (32).
Regional Variation in MELD Scores
Table 11 shows substantial variation in the MELD score at
which patients are transplanted among the 11 OPTN re-
gions. For example, in Region 6, 48% of recipients had
scores in the 11–20 range, more than twice the percent-
age of patients transplanted in this range in Regions 1,
5, 7, or 9. This disparity is seen in the higher ranges also.
This difference in transplantation is not seen in living donor
transplantation, where there appears to be little difference
between the regions.
Further data needs to be collected to examine these re-
gional variations. It is hoped that the allocation system will
in the future address these inequities of transplantation
rates, using the powerful tool that the MELD system pro-
vides.
Modeling Alternative Geographic
Distribution of Livers Under the
MELD/PELD System Using Simulation
Current liver allocation policy in the USA gives priority to
Status 1 candidates in the local distribution area (i.e. OPO
service area). Donor livers are next offered to Status 1 can-
didates within the region, and then to local candidates by
descending MELD/PELD score. This policy results in trans-
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plantation of local candidates with low MELD/PELD scores
even when there are high MELD/PELD candidates in other
OPOs elsewhere in the region. Modifying this geographic
ordering of candidates has been discussed as a means to
reduce waiting list mortality among high MELD/PELD can-
didates, but in the absence of a clinical trial there is a desire
to predict the effects of a modified geographic distribution
scheme.
The SRTR has developed a family of simulated allocation
modeling tools for use in exploring the effects of proposed
policy changes prior to implementation. The first of these
to be developed was the Liver Simulated Allocation Model
(LSAM). LSAM uses data from actual wait-listed candi-
dates and donor organs as inputs to an event-sequenced
Monte Carlo type simulation with specified allocation rules
and probabilistic models for organ acceptance and trans-
plant outcome. Using LSAM, the potential impact of a pol-
icy for regional sharing of livers for patients above defined
MELD/PELD thresholds has been examined.
Data from all adult and pediatric candidates on the liver
waiting list and all donor organs that became available be-
tween 4/1/02 and 10/1/02 were included in the simulation.
All simulated outcomes from the LSAM runs were esti-
mated for this 6-month timeframe.
Regional sharing of livers was examined by varying the
LSAM allocation rules. Two thresholds (25 and 35) were
tested to estimate the impact of regional sharing of organs
for MELD/PELD scores above each limit. The results from
these LSAM runs have been summarized and contrasted
with results from an LSAM simulation of regional sharing
for all MELD/PELD scores, as well as with current rules.
Exception allocation MELD scores as utilized in the exist-
ing national policy were set at 20 for small hepatocellular
carcinomas (HCC T1) and 24 for more extensive (HCC T2)
cases. Hepatocellular carcinoma patients were excluded
from sharing at the regional level. Results from the simula-
tion model for each set of rules tested were averaged over
10 separate runs to generate average outcome estimates.
For the allocation rule of regional sharing among all
MELD/PELD scores, LSAM offered livers first to Status
1 local patients, then to Status 1 regional patients. Follow-
ing Status 1 patients, allocation was by MELD/PELD at the
regional level according to the following order:
Group 1: Local, nonexception by MELD/(PELD).
Group 2: Local, exception (HCC).
Group 3: Regional, nonexception by MELD/(PELD).
Group 4: Regional, exception (HCC).
Initially the organ is offered among the pooled candi-
dates in Groups 1–3 according to descending allocation by
MELD/PELD. If there are ties at MELD/PELD, then ABO-
203 203 185 124
689 662 615 616
788 771
710 798
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Source: SRTR Analysis. Data as of August 1, 2003.
Figure 10: LSAM results for regional sharing by MELD/PELD
threshold, by MELD/PELD at transplant.
identical patients are offered the organ before the ABO-
compatible patients. If there are ties at that level, then the
organ is offered first to patients in Group 1, then to pa-
tients in Group 2, and finally to patients in Group 3. Group
4 patients would then be offered the organ, in descending
MELD/PELD order. Ties are broken by waiting time at or
above the MELD/PELD score. Finally, the organ is offered
to national patients, Status 1 first, and then MELD/PELD
patients in descending MELD/PELD order.
Regional sharing by MELD/PELD threshold was done as
described above for patients at or above the threshold.
Below the threshold, it was offered first to local patients in
descending MELD/PELD order (starting at threshold minus
1), then regionally by descending MELD/PELD.
Figure 10 shows the total number of transplants by
MELD/PELD that would result under each set of alloca-
tion rules tested. Using a MELD/PELD threshold of 35 for
regional sharing resulted in a 6% increase in the number
of transplants done at MELD/PELD 25 or greater. When
the threshold for regional sharing was lowered to 25, the
number of high MELD/PELD transplants increased by 26%
compared with current rules. Regional sharing for the full
MELD/PELD scale was associated with an intermediate
result, because more regional candidates with intermedi-
ate MELD/PELD scores would be available. Conversely,
regional sharing at the 35 threshold resulted in no reduc-
tion in the number of transplants at MELD/PELD below 10,
a 9% reduction at a threshold of 25, and a 39% reduction
using full regional sharing. Figure 11 shows the same data
displayed by whether the transplant was allocated locally
or within the OPTN region. As expected, lowering of the re-
gional sharing threshold yields progressively more regional
transplants.
As shown in Figure 12, simulation results suggest that re-
gional sharing increases the number of liver transplants for
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Source: SRTR Analysis. Data as of August 1, 2003.
Figure 11: LSAM results for regional sharing by MELD/PELD
threshold, local and regional transplants.
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Source: SRTR Analysis. Data as of August 1, 2003.
Figure 12: LSAM results for regional sharing by MELD/PELD
threshold, pediatric and adult transplants.
pediatric recipients by approximately 10%. Overall death
counts from the various regional sharing rules are given
in Figure 13. Reduction in total deaths (waiting list plus
post-waiting list removal plus post-transplant) were 1%,
3%, and 4% for LSAM runs with 35 threshold, 25 thresh-
old, and full regional sharing, respectively. Post-transplant
and post-waiting list removal deaths were not predicted
to change substantially, while waiting list deaths were re-
duced by 2%, 4%, and 6%, respectively.
While these LSAM results suggest that there may be a
reduction in waiting list mortality with regional sharing by
MELD/PELD, the resulting post-transplant mortality counts
may be understated, because these results do not fully
account for the potential adverse effect associated with
increased cold ischemia time with older donor organs on
post-transplant outcomes (33). Cold ischemia time is not
known at the time of organ offer, therefore it will need to
be estimated by LSAM based on transport time or geo-
graphic distance. There are plans to incorporate the pre-
dicted effects of cold ischemia time into the organ ac-
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Source: SRTR Analysis. Data as of August 1, 2003.
Figure 13: LSAM results for regional sharing by MELD/PELD
threshold, post-transplant deaths, waiting list and post-waiting list.
ceptance model and post-transplant survival model within
LSAM. Currently, the cold ischemia time effect is partially
accounted for by surrogate covariate adjustment in these
models (allocation to a local, regional or national candidate).
Finally, as suggested by DebRoy et al. an adjustment for
the interaction between geographic distribution and donor
age is made in the post-transplant survival model (33).
LSAM is a useful tool to examine new allocation pol-
icy proposals. As the model becomes more sophisti-
cated, additional analyses of detailed output data are
planned to further dissect the predicted results of LSAM
modeling.
Using MELD to Identify Expanded Criteria
Liver Donors
In recent years, the severe shortage of deceased donor
organs has driven transplant centers to broaden the char-
acteristics by which these organs are judged acceptable.
At first these donors were thought to be on the margins of
acceptability and were termed marginal donors, but with
more widespread use of organs from these donors, the
term expanded criteria donor (ECD) has become accepted.
In general, organs from such donors function less well and
may carry poorer short and long-term outcomes for their re-
cipients. As more experience is gained, medical and ethical
issues arise regarding the appropriate allocation of these
organs to recipients and the need to inform potential re-
cipients of the increased risks of poorer outcome when
these organs are used. For renal transplantation, these is-
sues have been recently outlined and codified in renal al-
location policy (34–36). The main driving force for imple-
mentation of such a policy was to develop a list of renal
transplant candidates who are willing to accept an ECD
kidney after having been informed that such an organ is
at higher risk of poorer or shorter function. In particular,
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a renal transplant candidate whose life expectancy is less
than the expected graft survival of an ECD kidney or less
than the expected wait for a non-ECD kidney may be ap-
propriate for the ECD list. Necessary for establishing policy
for ECD kidneys was the requirement that a definition of
ECD kidneys be characterized and donor risk factors asso-
ciated with this definition identified. In a previous analysis
by the SRTR, a relative risk of deceased donor kidney graft
failure of 1.7 was chosen to define an ECD kidney (34).
This criterion includes all deceased donors over 60 years
of age and those donors over age 50 with at least two
of the following: terminal serum creatinine ≥ 1.5 mg/dL,
cerebrovascular accident as the cause of death, or history
of hypertension. These risk factors have been incorporated
into renal allocation policy and serve to accurately inform
renal transplant candidates and practitioners that kidneys
from donors meeting these criteria may be appropriate for
candidates who are informed of and willing to accept the
risks (35).
The SRTR has recently completed a similar analysis to
define expanded criteria for livers from deceased donors
based on the same relative risk (RR = 1.7) for early graft
failure or death. For this analysis, the study population
consisted of 18 025 adult primary cadaveric liver trans-
plant recipients transplanted between 7/1/97 and 1/1/02
and followed through 8/1/02. Cox proportional hazards
models were fit to investigate the association of time to
graft failure or death with the donor and recipient factors.
Donor factors included age, sex, race, ethnicity, cause of
death, size (body mass index, and weight and height sepa-
rately), confirmed blood infection, use of three or more in-
otropic agents, dopamine or dobutamine use, partial or split
liver, diabetes, hypertension, creatinine, serum glutamic-
oxaloacetic transaminase (SGOT), serum glutamic-pyruvic
transaminase (SGPT), sodium >170 mEq/L, total bilirubin,
and percentage of fat on donor liver biopsy. Along with
year of transplant and cold ischemic time, recipient factors
included age, sex, race, ethnicity, body mass index (BMI),
medical urgency status at transplant, panel reactive anti-
body level >10%, New York Heart Association class, mus-
cle wasting, ventilator use, dialysis dependency, serum
creatinine, serum albumin, serum bilirubin, and ABO com-
patibility. Additional ascertainment of death from the Social
Security Death Master File (SSDMF) was integrated with
available OPTN post-transplant follow-up. A relative risk of
1.7 was chosen as a cut-off for inclusion in the ECD group.
Donor risk factors associated with a statistically significant
increased relative risk of graft failure are summarized in Ta-
ble 12. Risk factors associated with the largest increased
risk were: donor age >65 years, donor age <9 years, partial
or split liver, and donor age 50–64 years.
Table 13 depicts a matrix indicating which donor variables
or combination of variables results in a relative risk of graft
failure or death ≥1.7. All donors aged 70 and older had a
relative risk of graft failure ≥1.7. Donors aged 60–69 years
with at least one of the following donor factors also had
a relative risk of graft failure or death ≥1.7. Donors 40–
59 years of age who had at least two additional donor
factors or were donors of split/partial grafts had a rela-
tive risk of graft failure ≥ 1.7. The only ECD donors in the
18–39 year range were those whose livers were used for
split/partial grafts. Using the study cohort (transplants per-
formed 7/1/97–1/1/02), this definition categorizes 15.9% of
transplanted livers as ECD and 20.9% of recovered ECD
livers as not transplanted, compared with 9.9% of non-ECD
livers.
Defining an ECD liver donor by a relative risk of graft fail-
ure of 1.7 may be inappropriately high because graft failure
after liver transplantation has more severe consequences
than graft failure after renal transplantation. In the future,
investigators may want to consider a lower relative risk of
graft failure as more in balance with the risk that the recipi-
ent of a failed liver graft faces. In the absence of analyses to
justify a lower relative risk definition, however, it is useful
to apply the working definition to analyses of graft recovery
and usage under the MELD/PELD system of allocation to
assess which candidates are receiving these grafts.
Interestingly, the number of deceased donors increased
only 3.5% in the first year of the MELD/PELD allocation
compared with the year prior to implementation. Nonethe-
less, the transplantation rate using deceased donors in-
creased significantly (272 per 1000-patient years in the year
prior to MELD/PELD vs. 300 per 1000-patient years under
the MELD/PELD system, p < 0.001). This may be due to
an increase in the ratio of donors transplanted/donors re-
covered (90.5 vs. 92.5, p < 0.005) under the MELD/PELD
system, suggesting an increased use of ECD donor livers.
In an analysis of 30-day outcomes under the MELD/PELD
system, the SRTR examined the transplantation rate for
ECD donor livers among adult recipients, stratified by
MELD score at the time of transplant. The results of this
analysis are summarized in Figure 14. The overall trans-
plantation rate within 30 days of listing for all adult candi-
dates, stratified by MELD range, increases from 2% for the
lowest range to 65% for candidates in the 30–40 range.
When considering livers recovered from donors meeting
the above ECD criteria, however, nearly 30% of all trans-
plants performed for candidates in the lowest decile of
MELD score are done with ECD livers. This rate decreases
in each higher MELD range except the 30–40 category.
Even for these most urgent candidates only 10% of the
transplants are performed with ECD donors. This suggests
that centers are utilizing livers from ECD donors preferen-
tially for the least ill recipients.
These are preliminary analyses and future work must be
done to define the criteria associated with the appropri-
ate risk of graft failure for recipients of deceased donor
livers that should be considered expanded. Once done,
however, informing potential recipients of these organs of
the increased risks they face will be necessary.
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Table 12: Donor risk factors associated with a statistically significant increased relative risk of graft failure
Donor risk factors∗ Percentage of donors RR p-value
Partial or split liver 1.6 1.52 0.0002
Serum sodium prior to procurement >170 mEq/L 2.4 1.31 0.0051
Cardiac arrest since neurological event 2.0 1.33 0.0065
Cause of death: cerebrovascular/stroke 42.8 1.16 0.0003
Cause of death: missing 0.9 1.19 0.3045
Cause of death: anoxia/cardiac arrest 8.2 1.09 0.1711
Cause of death: CNS tumor 1.1 1.25 0.1037
Cause of death: other 1.9 1.14 0.2298
Donor weight (per 10 kg under 70 kg) 1.03 0.0038
Black race (vs. white) 11.6 1.23 <0.0001
Asian race 1.9 1.00 0.9615
Other race 0.7 1.34 0.0902
Donor age 0–9 (vs. age 10–39) 1.5 1.68 <0.0001
Donor age 40–49 18.5 1.18 0.0004
Donor age 50–64 21.0 1.36 <0.0001
Donor age 65 or greater 8.0 1.73 <0.0001
Source: SRTR analysis (36). ∗Cox regression model was also adjusted for cold ischemia time and the following recipient characteristics:
status, BMI, NYHC functional status, age, race, PRA > 10, ventilator use, and serum creatinine.
Table 13: Expanded criteria for liver donors
Donor age categories
Donor condition 18–39 40–49 50–59 60–69 ≥70
None Ref. X
Arrest or CVA or Na > 170 X X
Arrest and CVA X X X X
Split/partial; all
other combinations X X X X X
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Source: SRTR Analysis. Data as of August 1, 2003.
Figure 14: Thirty-day liver transplant rate by MELD/PELD score
and ECD status.
Future Directions
The new MELD/PELD system represents a departure from
previous organ allocation policy. Waiting time, still the most
important ranking criterion for kidney, pancreas, lung, and
some heart candidates, has been almost entirely removed
from liver allocation. The new system does not categorize
patients into groups but utilizes a continuous score. These
two important changes, combined with the removal of the
CTP score’s subjective clinical factors, have resulted in a
more patient-specific system that allows for better mea-
surement and transparency.
Hepatocellular carcinoma remains a significant clinical chal-
lenge. With more than 14 000 new cases diagnosed each
year, this single indication for transplantation has the po-
tential to overwhelm the system. Future allocation policy
will require more precise diagnostic modalities and a much
better understanding of the natural history of progression
to more fairly assign the correct priority for these patients
based on their risk of progression beyond a stage favorable
for transplantation. Additional refinements in defining the
favorable stage itself will also be required.
Geographic differences in transplantation rates, distribu-
tion of MELD/PELD scores at transplant, and differences
in RRB policies will also need to be addressed. The
MELD/PELD system addresses only allocation priority; it
does not affect distribution units, defined as the small-
est group of patients prioritized for a particular organ once
it becomes available. In most cases, the distribution unit
for liver allocation is all the patients wait-listed in all the
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centers served by a single organ procurement organiza-
tion (OPO). There are currently many factors that make
distribution units heterogeneous, such as number of brain
deaths within the OPO’s service area, efficiency with which
the OPO identifies and retrieves the organs from these
donors, the number of candidates waiting at the centers
in that OPO, the number of centers within the OPO, and
the listing practice and organ acceptance practice of each
center within the OPO (38). These all contribute to varia-
tions in MELD/PELD score at the time of organ offer. The
MELD/PELD system gives the liver transplant community
a precise measurement of such differences. Regional shar-
ing for candidates with MELD scores over a certain value
might be one way to help direct more organs to those most
likely to die without a transplant. Also, a better understand-
ing of the mortality risks faced by waiting candidates based
on the MELD score may allow for development of minimal
listing or minimal transplantation criteria based on the risk
of death with or without the transplant. This potentially
could reduce the number liver transplants for candidates
who have a higher risk of death from the transplant surgery
than they have waiting for an additional 6–12 months.
The analysis of ECD livers also opens the possibility of
matching recipients based on their risks of death without a
transplant and donors based on their risks of graft failure to
optimize the donor pool. Combining pretransplant mortality
risk models with post-transplant survival models may also
allow liver allocation policy to evolve towards maximizing
the benefit of transplantation so that organs are directed to
those with a high risk of dying without the transplant and
with the highest net survival with the transplant.
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